Product
Fluzoparib+Apatinib
1 clinical trial
4 indications
Indication
Ovarian CancerIndication
Primary Peritoneal CarcinomaIndication
Fallopian tube cancerClinical trial
A Randomized, Multicenter, Noncomparative Clinical Study of Fluzoparib With or Without Apatinib for Maintenance Therapy in PARPi-pretreated Platinum-sensitive Recurrent Ovarian CancerStatus: Not yet recruiting, Estimated PCD: 2025-03-10